BMS pays $65M to expand Repertoire of autoimmune assets
CAMBRIDGE, Mass., April 29, 2024 /PRNewswire/ -- Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted immune medicines, announced today that it has entered a multi-year strategic collaboration with Bristol Myers Squibb (NYSE: BMY) to develop tolerizing vaccines for up to three autoimmune diseases. The collaboration aims to develop efficacious, selective, and durable treatments for patients suffering from autoimmune disease by resetting the immune system.
Repertoire® Immune Medicines Presents New Data From Its DECODE™ Platform Identifying Highly Prevalent Immunotherapeutic Targets in HPV-Positive Cancers, Unlocking Pathways for Potential Therapeutics
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Repertoire® Immune Medicines announced today that Torben Straight Nissen has been appointed as interim Chief Executive Officer, succeeding John Cox, who will continue with the company in an advisory role. With more than two decades of leadership experience, Straight Nissen joins the company as it shifts its resources and operations to focus primarily on unlocking the potential of Repertoire’s DECODE™ Platform to develop transformative immune medicines against novel immune targets in cancer, autoimmune disorders, and infectious disease.
Less than three years into its existence, Repertoire Immune Medicines is completely overhauling the company, axing its top two assets, replacing its CEO and cutting almost half of its staff.
Flagship Pioneering-founded Repertoire Immune Medicines has cut 45% its staff, or roughly 60 employees, the company confirmed to Fierce Biotech.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Repertoire® Immune Medicines will present data from its ongoing research to characterize the cellular response and identify novel therapeutic targets with the company’s DECODE™ platform in human papillomavirus (HPV) 16 and HPV 33 positive tumors. This research will be presented at the Society for Immunotherapy of Cancer (SITC 2022) 37th Annual Meeting, November 8-12, in Boston, Massachusetts.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Repertoire Immune Medicines announced today that Science Advances published preclinical research demonstrating the company’s cell-tethering technology can deliver the potent cytokine interleukin-12 (IL-12) to solid tumors without eliciting the severe systemic toxicities typically associated with the use of this cytokine. The research, conducted in mouse models, found that the use of cell-tethered IL-12 elevated anti-tumor activity in the immunosuppressive tumor microenvironment (TME).
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Repertoire Immune Medicines, announced today that Science Immunology published the company’s research showing that human leukocyte antigen (HLA) genotype significantly influenced the immune recall of CD8+ T cells (cytotoxic T lymphocytes) in reaction to SARS-CoV-2 infection. The paper, “Allelic variation in Class I HLA determines CD8+ T cell repertoire shape and cross-reactive memory responses to SARS-CoV-2”, was published online today in Science Immunology.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Repertoire Immune Medicines announced today that the first patient has been dosed in the company’s Phase 1 study of RPTR-168 (PRIME IL-12) in patients with select relapsed or refractory human papillomavirus (HPV)-16-positive tumors.